These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 27694903)
1. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903 [TBL] [Abstract][Full Text] [Related]
2. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression. Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219 [TBL] [Abstract][Full Text] [Related]
3. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901 [TBL] [Abstract][Full Text] [Related]
4. CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation. Haque I; Banerjee S; De A; Maity G; Sarkar S; Majumdar M; Jha SS; McGragor D; Banerjee SK Oncogene; 2015 Jun; 34(24):3152-63. PubMed ID: 25132260 [TBL] [Abstract][Full Text] [Related]
5. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573 [TBL] [Abstract][Full Text] [Related]
6. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320 [TBL] [Abstract][Full Text] [Related]
7. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A. Andriani L; Ling YX; Yang SY; Zhao Q; Ma XY; Huang MY; Zhang YL; Zhang FL; Li DQ; Shao ZM Cancer Lett; 2024 Aug; 597():217008. PubMed ID: 38849012 [TBL] [Abstract][Full Text] [Related]
8. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514 [TBL] [Abstract][Full Text] [Related]
9. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. Li M; Li A; Zhou S; Lv H; Yang W J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer. Li X; Song C; Wang K; Li N; Sun S; Li N; Zhao Z; Li M Cancer Biomark; 2019; 25(1):19-27. PubMed ID: 31033460 [TBL] [Abstract][Full Text] [Related]
11. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452 [TBL] [Abstract][Full Text] [Related]
12. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer. Chen W; Liang JL; Zhou K; Zeng QL; Ye JW; Huang MJ Cell Commun Signal; 2020 Apr; 18(1):67. PubMed ID: 32321509 [TBL] [Abstract][Full Text] [Related]
13. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Yang X; Qu K; Tao J; Yin G; Han S; Liu Q; Sun H Biochem Biophys Res Commun; 2018 Jan; 495(2):1807-1814. PubMed ID: 29175329 [TBL] [Abstract][Full Text] [Related]
15. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis. Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585 [TBL] [Abstract][Full Text] [Related]
16. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Khanna A; Pimanda JE; Westermarck J Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027 [TBL] [Abstract][Full Text] [Related]
17. CIP2A is associated with human breast cancer aggressivity. Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842 [TBL] [Abstract][Full Text] [Related]
18. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Kim JS; Kim EJ; Oh JS; Park IC; Hwang SG Cancer Res; 2013 Nov; 73(22):6667-78. PubMed ID: 23983103 [TBL] [Abstract][Full Text] [Related]
19. Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy. Li S; Feng TT; Guo Y; Yu X; Huang Q; Zhang L; Tang W; Liu Y Oncol Lett; 2016 Dec; 12(6):5370-5376. PubMed ID: 28101248 [TBL] [Abstract][Full Text] [Related]
20. Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer. Yin J; Chen D; Luo K; Lu M; Gu Y; Zeng S; Chen X; Song Y; Zhang Z; Zheng G; He Z; Liu H J Cancer; 2019; 10(24):5964-5974. PubMed ID: 31762806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]